Advances in Cardiovascular Drug Therapies (Technical Insights)

Publication Date	March 2008
Publisher	Frost & Sullivan
Product Type	Report
Pages
ISBN Number	not applicable
Product Code	FRS00645

Buy this product or for assistance call +44 20 7060 7474

PDF £3,910.00$6504 | €4376

FAX Order above formats by FAX

Summary

This research service outlines the key global developments in cardiovascular drug therapies.

Content

Executive summary
- Scope and methodology
  - Scope and segmentation
  - Methodology
- Industry overview
  - Brief summary of cardiovascular drug industry
  - Key findings and noteworthy developments
Technology adoption factor analysis
- Emerging trends in cardiovascular drug therapy; research and development
  - Cvds and drug classes
  - Emerging trends in cardiovascular drug therapy
  - Cardiovascular pharmacogenomics--a major trend in cardiovascular research
  - Emerging trends in cardiovascular biomarkers--diagnostic; prognostic; and therapeutic insights
  - Emerging molecular therapeutics and their impact on cvd drug development
- Strategic analysis and recommendations
  - Analysis of drivers for cardiovascular pharmaceutical industry
  - Impact of challenges and restraints on cardiovascular pharmaceuticals
  - Product life cycle analysis and strategic recommendations
  - Opportunity analysis
  - Acquisitions; partnerships; and technology licensing between companies and research organizations
Global developments in cardiovascular drugs
- Corporate developments--world
  - Blockbuster drug to treat hypercholesterolemia--usa
  - Novel antisense drug for cholesterol management--usa
  - Novel direct acting aptamer-based anticoagulant--usa
  - Novel drug candidates to treat cardiac reperfusion induced heart failure--israel
  - Breakthrough technology platform and novel drug to increase hdl levels--canada
  - Cardioprotective effects of a naturally occurring peptide--usa
  - Novel drugs for acute coronary syndrome--canada
  - Sonolysis-based tpa therapy for ischemic stroke patients--usa
  - Dna-based therapeutic to treat angina--usa
  - Selective thyroid hormone agonist lowers ldl levels--sweden
  - Novel drug to treat diabetic and nondiabetic heart failure--new zealand
  - Novel drug with better safety and tolerability profile for atrial fibrillation--usa
- Academic developments--world
  - Ppar-delta as a potential drug target for treating atherosclerosis--usa
  - Discovery of genetic link to bad cholesterol raises hope for specific therapy--uk
  - Potential of a novel compound to reduce the impact of heart attack in humans--usa
Intellectual property scenario and key industry participants
- Patent details and patent analysis
  - Corporate patents
  - Academic patents
- Contact details
  - Industry contacts
  - University contacts
Decision support database
- Decision support tables
  - Hypertension prevalence--world (2002 to 2012)
  - New cases of heart attack--world (2002 to 2012)
  - New cases of stroke--world (2002 to 2012)
  - Population aged 65 years and above--world (2002 to 2012)
  - Prevalence of diabetes--world (2002 to 2012)
  - Pharmaceutical r&d expenditure--world (2002 to 2012)